Abstract
Background
This study assessed whether primary tumor maximum standardized uptake value (pSUVmax) measured by 18F-fluoro-2-deoxy-d-glucose (18F-FDG) positron emission tomography/computed tomography (PET/CT) could improve the prediction of axillary lymph node (ALN) metastasis in invasive ductal breast cancer (IDC).
Methods
In this study, 128 IDC patients who underwent pretreatment 18F-FDG PET/CT and surgical resection of primary tumor with sentinel lymph node biopsy, ALN dissection, or both were analyzed. All the patients were classified as five molecular subtypes. The optimal cutoff values of pSUVmax for all the patients and each molecular subtype for the prediction of ALN metastasis were determined using receiver operating characteristic (ROC) analysis. Furthermore, the prognostic accuracy of ALN metastasis was assessed using c-statistics.
Results
The findings showed ALN metastasis in 52 patients (40.6%). The 18F-FDG PET/CT procedure had a sensitivity of 48.1% and a specificity of 94.7% for ALN metastasis. In the ROC analysis of pSUVmax for ALN metastasis, the optimal cutoff value was 3.9 for all the patients, 2.8 for the luminal A subtype, 3.3 for the luminal B (human epidermal growth factor receptor 2 [HER2]-negative) subtype, 5.3 for the luminal B (HER2-positive) subtype, 12.7 for the HER2-positive subtype, and 11.5 for the triple-negative subtype. A predictive ALN metastasis model using nodal 18F-FDG uptake finding gave a c-statistic of 0.714, and a model combination of nodal 18F-FDG uptake finding with pSUVmax of all the patients gave a c-statistic of 0.736 (P = 0.3926). However, the combination of nodal the 18F-FDG uptake finding with the pSUVmax of each molecular subtype gave a c-statistic of 0.791 (P = 0.0047).
Conclusions
Combining the pSUVmax of each molecular subtype with the nodal 18F-FDG uptake finding can improve the prediction of ALN metastasis in IDC.
Similar content being viewed by others
References
American Cancer Society. Cancer Facts & Figures 2016. American Cancer Society, Atlanta, 2016.
Banerjee M, George J, Song EY, Roy A, Hryniuk W. Tree-based model for breast cancer prognostication. J Clin Oncol. 2004;22:2567–75.
Lavayssière R, Cabée A-E, Filmont J-E. Positron emission tomography (PET) and breast cancer in clinical practice. Eur J Radiol. 2009;69:50–8.
Wang Y, Zhang C, Liu J, Huang G. Is 18F-FDG PET accurate to predict neoadjuvant therapy response in breast cancer? A meta-analysis. Breast Cancer Res Treat. 2012;131:357–69.
Dialani V, Chadashvili T, Slanetz PJ. Role of imaging in neoadjuvant therapy for breast cancer. Ann Surg Oncol. 2015;22:1416–24.
Wahl RL. Prospective multicenter study of axillary nodal staging by positron emission tomography in breast cancer: a report of the staging breast cancer with PET study group. J Clin Oncol. 2003;22:277–85.
Veronesi U, De Cicco C, Galimberti V, Fernandez JR, Rotmensz N, Viale G et al. A comparative study on the value of FDG-PET and sentinel node biopsy to identify occult axillary metastases. Ann Oncol. 2006;18:473–8.
Heusner TA, Kuemmel S, Hahn S, Koeninger A, Otterbach F, Hamami ME, et al. Diagnostic value of full-dose FDG PET/CT for axillary lymph node staging in breast cancer patients. Eur J Nucl Med Mol Imaging. 2009;36:1543–50.
Pritchard KI, Julian JA, Holloway CMB, McCready D, Gulenchyn KY, George R, et al. Prospective study of 2-[18F]fluorodeoxyglucose positron emission tomography in the assessment of regional nodal spread of disease in patients with breast cancer: an Ontario clinical oncology group study. J Clin Oncol. 2012;30:1274–9.
Jung J, Kim C-Y, Son SH, Kim DH, Jeong SY, Lee SW, et al. Preoperative prediction of cervical lymph node metastasis using primary tumor SUVmax on 18F-FDG PET/CT in patients with papillary thyroid carcinoma. PLoS ONE. 2015;10:e0144152.
Kim D-H, Song B-I, Hong CM, Jeong SY, Lee SW, Lee J, et al. Metabolic parameters using 18F-FDG PET/CT correlate with occult lymph node metastasis in squamous cell lung carcinoma. Eur J Nucl Med Mol Imaging. 2014;41:2051–7.
Tsutani Y, Miyata Y, Nakayama H, Okumura S, Adachi S, Yoshimura M, et al. Prediction of pathologic node-negative clinical stage IA lung adenocarcinoma for optimal candidates undergoing sublobar resection. J Thorac Cardiovasc Surg. 2012;144:1365–71.
Jung NY, Kim SH, Kang BJ, Park SY, Chung MH. The value of primary tumor 18F-FDG uptake on preoperative PET/CT for predicting intratumoral lymphatic invasion and axillary nodal metastasis. Breast Cancer. 2016;23:712–7.
Kim JY, Lee SH, Kim S, Kang T, Bae YT. Tumor 18 F-FDG uptake on preoperative PET/CT may predict axillary lymph node metastasis in ER-positive/HER2-negative and HER2-positive breast cancer subtypes. Eur Radiol. 2015;25:1172–81.
Moon SH, Kim HS, Hyun SH, Choi YS, Zo JI, Shim YM, et al. Prediction of occult lymph node metastasis by metabolic parameters in patients with clinically N0 esophageal squamous cell carcinoma. J Nucl Med. 2014;55:743–8.
Mavi A, Cermik TF, Urhan M, Puskulcu H, Basu S, Jian QY, et al. The effects of estrogen, progesterone, and C-erbB-2 receptor states on 18F-FDG uptake of primary breast cancer lesions. J Nucl Med. 2007;48:1266–72.
Song B-I, Hong CM, Lee HJ, Kang S, Jeong SY, Kim HW, et al. Prognostic value of primary tumor uptake on F-18 FDG PET/CT in patients with invasive ductal breast cancer. Nucl Med Mol Imaging. 2011;45:117–24.
Kitajima K, Fukushima K, Miyoshi Y, Nishimukai A, Hirota S, Igarashi Y, et al. Association between 18F-FDG uptake and molecular subtype of breast cancer. Eur J Nucl Med Mol Imaging. 2015;42:1371–7.
García Vicente AM, Soriano Castrejón Á, León Martín A, López-Muñiz IC, Madero VM, Sánchez MD, et al. Molecular subtypes of breast cancer: metabolic correlation with 18F-FDG PET/CT. Eur J Nucl Med Mol Imaging. 2013;40:1304–11.
Wolff AC, Hammond MEH, Schwartz JN, Hagerty KL, Allred DC, Cote RJ, et al. American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer. Arch Pathol Lab Med. 2007;131:18–43.
Goldhirsch A, Wood WC, Coates AS, Gelber RD, Thürlimann B, Senn HJ, et al. Strategies for subtypes-dealing with the diversity of breast cancer: highlights of the St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2011. Ann Oncol. 2011;22:1736–47.
Hodgson NC, Gulenchyn KY. Is there a role for positron emission tomography in breast cancer staging? J Clin Oncol. 2008;26:712–20.
Crabb SJ, Cheang MCU, Leung S, Immonen T, Nielsen TO, Huntsman DD, et al. Basal breast cancer molecular subtype predicts for lower incidence of axillary lymph node metastases in primary breast cancer. Clin Breast Cancer. 2008;8:249–56.
He Z-Y, Wu S-G, Yang Q, Sun JY, Li FY, Lin Q, et al. Breast cancer subtype is associated with axillary lymph node metastasis: a retrospective cohort study. Medicine Baltimore. 2015;94:e2213.
Fletcher JW, Djulbegovic B, Soares HP, Siegel BA, Lowe VJ, Lyman GH, et al. Recommendations on the use of 18F-FDG PET in oncology. J Nucl Med. 2008;49:480–508.
Groheux D, Cochet A, Humbert O, Alberini J-L, Hindie E, Mankoff D. 18F-FDG PET/CT for staging and restaging of breast cancer. J Nucl Med. 2016;57:17S–26S.
Oshida M, Uno K, Suzuki M, Nagashima T, Hashimoto H, Yagata H, et al. Predicting the prognoses of breast carcinoma patients with positron emission tomography using 2-deoxy-2-fluoro[18F]-d-glucose. Cancer. 1998;82:2227–34.
Lyman GH, Giuliano AE, Somerfield MR, Benson III AB, Bodurka DC, Burstein HJ, et al. American Society of Clinical Oncology guideline recommendations for sentinel lymph node biopsy in early stage breast cancer. J Clin Oncol. 2005;23:7703–20.
Soret M, Bacharach SL, Buvat I. Partial-volume effect in PET tumor imaging. J Nucl Med. 2007;48:932–45.
Acknowledgment
This research was supported by the National Research Foundation of Korea (NRF) Grant funded by the Korea Government (MSIP) (No. 2014R1A5A2010008).
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Disclosure
There are no conflicts of interest.
Rights and permissions
About this article
Cite this article
Song, BI., Kim, H.W. & Won, K.S. Predictive Value of 18F-FDG PET/CT for Axillary Lymph Node Metastasis in Invasive Ductal Breast Cancer. Ann Surg Oncol 24, 2174–2181 (2017). https://doi.org/10.1245/s10434-017-5860-0
Received:
Published:
Issue Date:
DOI: https://doi.org/10.1245/s10434-017-5860-0